From toxoplasmosis to schizophrenia via NMDA dysfunction: Peptide overlap between Toxoplasma Gondii and n-methyl-d-aspartate receptors as a potential mechanistic link

Frontiers in Psychiatry

Volumn 8, Issue MAR, 2017, Pages

  Lucchese, Guglielmo ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Gamma oscillations; Immune cross reactivity; N methyl d aspartate receptors; NMDA 2D; Parvalbumin positive interneurons; Peptide commonality; Schizophrenia; Toxoplasma gondii

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2C; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2D; PARVALBUMIN; PROTEOME;

AMINO ACID SEQUENCE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; HUMAN; IMMUNE RESPONSE; INTERNEURON; NONHUMAN; PATHOGENESIS; SCHIZOPHRENIA; SEQUENCE ANALYSIS; TOXOPLASMA GONDII; TOXOPLASMOSIS;

EID: 85016139122     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2017.00037     Document Type: Article

References (82)

1. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet (2016) 388:86-97. doi:10.1016/S0140-6736(15)01121-6
2. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci (2008) 31:234-42. doi:10.1016/j.tins.2008.02.005
3. Yolken RH, Dickerson FB, Fuller Torrey E. Toxoplasma and schizophrenia. Parasite Immunol (2009) 31:706-15. doi:10.1111/j.1365-3024.2009.01131.x
4. Tomasik J, Schultz TL, Kluge W, Yolken RH, Bahn S, Carruthers VB. Shared immune and repair markers during experimental Toxoplasma chronic brain infection and schizophrenia. Schizophr Bull (2016) 42:386-95. doi:10.1093/schbul/sbv134
5. Dickerson F, Boronow J, Stallings C, Origoni A, Yolken R. Toxoplasma gondii in individuals with schizophrenia: association with clinical and demographic factors and with mortality. Schizophr Bull (2007) 33:737-40. doi:10.1093/schbul/sbm005
6. Mortensen P, Norgaard-Pedersen B, Waltoft B, Sorensen T, Hougaard D, Yolken R. Early infections of Toxoplasma gondii and the later development of schizophrenia. Schizophr Bull (2007) 33:741-4. doi:10.1093/schbul/sbm009
7. Wang HL, Wang GH, Li QY, Shu C, Jiang MS, Guo Y. Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia. Acta Psychiatr Scand (2006) 114:40-8. doi:10.1111/j.1600-0447.2006.00780.x
8. Torrey EF, Bartko JJ, Lun ZR, Yolken RH. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr Bull (2007) 33:729-36. doi:10.1093/schbul/sbl050
9. Hamidinejat H, Ghorbanpoor M, Hosseini H, Alavi SM, Nabavi L, Jalali MHR, et al. Toxoplasma gondii infection in first-episode and inpatient individuals with schizophrenia. Int J Infect Dis (2010) 14:e978-81. doi:10.1016/j.ijid.2010.05.018
10. Sutterland AL, Fond G, Kuin A, Koeter MW, Lutter R, van Gool T, et al. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. Acta Psychiatr Scand (2015) 132:161-79. doi:10.1111/acps.12423
11. Torrey EF, Bartko JJ, Yolken RH. Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr Bull (2012) 38:642-7. doi:10.1093/schbul/sbs043
12. Monroe JM, Buckley PF, Miller BJ. Meta-analysis of anti-Toxoplasma gondii IgM antibodies in acute psychosis. Schizophr Bull (2015) 41:989-98. doi:10.1093/schbul/sbu159
13. Brown AS, Schaefer CA, Quesenberry CP Jr, Liu L, Babulas VP, Susser ES. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry (2005) 162:767-73. doi:10.1176/appi.ajp.162.4.767
14. Mortensen PB, Nørgaard-Pedersen B, Waltoft BL, Sørensen TL, Hougaard D, Torrey EF, et al. Toxoplasma gondii as a risk factor for schizophrenia: analysis of filter paper blood samples obtained at birth. Biol Psychiatry (2007) 61:688-93. doi:10.1016/j.biopsych.2006.05.024
15. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res (1999) 33:523-33. doi:10.1016/S0022-3956(99)00029-1
16. Javitt DC. Glutamate and schizophrenia: phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol (2007) 78:69-108. doi:10.1016/S0074-7742(06)78003-5
17. Javitt DC. Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci (2010) 47:4-16.
18. Javitt DC. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry (1987) 9:12-35.
19. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry (1991) 148:1301-8. doi:10.1176/ajp.148.10.1301
20. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 51:199-214. doi:10.1001/archpsyc.1994.03950030035004
21. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport (1995) 6:869-72. doi:10.1097/00001756-199504190-00011
22. Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia? Brain Res Bull (2010) 83:108-21. doi:10.1016/j.brainresbull.2010.04.006
23. Coyle JT. NMDA receptor and schizophrenia: a brief history. Schizophr Bull (2012) 38:920-6. doi:10.1093/schbul/sbs076
24. Hall J, Trent S, Thomas KL, O'Donovan MC, Owen MJ. Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity. Biol Psychiatry (2015) 77:52-8. doi:10.1016/j.biopsych.2014.07.011
25. Veerman SR, Schulte PF, de Haan L. The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged. Pharmacopsychiatry (2014) 47:121-30. doi:10.1055/s-0034-1383657
26. Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol (2015) 29:97-115. doi:10.1177/0269881114563634
27. Snyder MA, Gao WJ. NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Front Cell Neurosci (2013) 7:31. doi:10.3389/fncel.2013.00031
28. Harris LW, Sharp T, Gartlon J, Jones DN, Harrison PJ. Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism. Eur J Neurosci (2003) 18:1706-10. doi:10.1046/j.1460-9568.2003.02902.x
29. Frohlich J, Van Horn JD. Reviewing the Ketamine Model for schizophrenia. J Psychopharmacol (2014) 28:287-302. doi:10.1177/0269881113512909
30. Oldstone MB. Molecular mimicry and immune-mediated diseases. FASEB J (1998) 12:1255-65.
31. Kohm A, Fuller K, Miller S. Mimicking the way to autoimmunity: an evolving theory of sequence and structural homology. Trends Microbiol (2003) 11:101-5. doi:10.1016/S0966-842X(03)00006-4
32. Pearlman DM, Najjar S. Meta-analysis of the association between N-methyl-d-aspartate receptor antibodies and schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder. Schizophr Res (2014) 157:249-58. doi:10.1016/j.schres.2014.05.001
33. Tsutsui K, Kanbayashi T, Tanaka K, Boku S, Ito W, Tokunaga J, et al. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC Psychiatry (2012) 12:37. doi:10.1186/1471-244X-12-37
34. Zandi MS, Irani SR, Lang B, Waters P, Jones PB, McKenna P, et al. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol (2011) 258:686-8. doi:10.1007/s00415-010-5788-9
35. Steiner J, Walter M, Glanz W, Sarnyai Z, Bernstein HG, Vielhaber S, et al. Increased prevalence of diverse N-methyl-d-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-d-aspartate glutamate receptor encephalitis. JAMA Psychiatry (2013) 70:271-8. doi:10.1001/2013.jamapsychiatry.86
36. Dickerson F, Stallings C, Vaughan C, Origoni A, Khushalani S, Yolken RH. Antibodies to the glutamate receptor in mania. Bipolar Disord (2012) 14:547-53. doi:10.1111/j.1399-5618.2012.01028.x
37. Deakin J, Lennox BR, Zandi MS. Antibodies to the N-methyl-d-aspartate receptor and other synaptic proteins in psychosis. Biol Psychiatry (2014) 75:284-91. doi:10.1016/j.biopsych.2013.07.018
38. Kannan G, Crawford JA, Yang C, Gressitt KL, Ihenatu C, Krasnova IN, et al. Anti-NMDA receptor autoantibodies and associated neurobehavioral pathology in mice are dependent on age of first exposure to Toxoplasma gondii. Neurobiol Dis (2016) 91:307-14. doi:10.1016/j.nbd.2016.03.005
39. UniProt Consortium. The universal protein resource (UniProt) 2009. Nucleic Acids Res (2009) 37:D169-74. doi:10.1093/nar/gkn664
40. Chen C, Li Z, Huang H, Suzek BE, Wu CH, UniProt Consortium. A fast Peptide Match service for UniProt knowledgebase. Bioinformatics (2013) 29:2808-9. doi:10.1093/bioinformatics/btt484
41. Vita R, Zarebski L, Greenbaum JA, Emami H, Hoof I, Salimi N, et al. The immune epitope database 2.0. Nucleic Acids Res (2010) 38:D854-62. doi:10.1093/nar/gkp1004
42. Frank A. Immunology and Evolution of Infectious Disease. Princeton, NJ: Princeton University Press (2002).
43. Zeng W, Pagnon J, Jackson DC. The C-terminal pentapeptide of LHRH is a dominant B cell epitope with antigenic and biological function. Mol Immunol (2007) 44:3724-31. doi:10.1016/j.molimm.2007.04.004
44. Kanduc D. Pentapeptides as minimal functional units in cell biology and immunology. Curr Protein Pept Sci (2013) 14:111-20. doi:10.2174/1389203711314020003
45. Ralston KS. Taking a bite: amoebic trogocytosis in Entamoeba histolytica and beyond. Curr Opin Microbiol (2015) 28:26-35. doi:10.1016/j.mib.2015.07.009
46. Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci (2013) 14:383-400. doi:10.1038/nrn3504
47. Watanabe M, Inoue Y, Sakimura K, Mishina M. Developmental changes in distribution of NMDA receptor channel subunit mRNAs. Neuroreport (1992) 3:1138-40. doi:10.1097/00001756-199212000-00027
48. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron (1994) 12:529-40. doi:10.1016/0896-6273(94)90210-0
49. Standaert DG, Landwehrmeyer GB, Kerner JA, Penney JB Jr, Young AB. Expression of NMDAR2D glutamate receptor subunit mRNA in neurochemically identified interneurons in the rat neostriatum, neocortex and hippocampus. Brain Res Mol Brain Res (1996) 42:89-102. doi:10.1016/S0169-328X(96)00117-9
50. Thompson CL, Drewery DL, Atkins HD, Stephenson FA, Chazot PL. Immunohistochemical localization of N-methyl-d-aspartate receptor subunits in the adult murine hippocampal formation: evidence for a unique role of the NR2D subunit. Brain Res Mol Brain Res (2002) 102:55-61. doi:10.1016/S0169-328X(02)00183-3
51. von Engelhardt J, Bocklisch C, Tönges L, Herb A, Mishina M, Monyer H. GluN2D-containing NMDA receptors-mediate synaptic currents in hippocampal interneurons and pyramidal cells in juvenile mice. Front Cell Neurosci (2015) 9:95. doi:10.3389/fncel.2015.00095
52. Ewald RC, Cline HT. NMDA receptors and brain development. In: Van Dongen AM, editor. Biology of the NMDA Receptor. Boca Raton, FL: CRC Press/Taylor & Francis (2009). p. 1-15.
53. Kehoe LA, Bernardinelli Y, Muller D. GluN3A: an NMDA receptor subunit with exquisite properties and functions. Neural Plast (2013) 2013:145387. doi:10.1155/2013/145387
54. Laurie DJ, Seeburg PH. Regional and developmental heterogeneity in splicing of the rat brain NMDAR1 mRNA. J Neurosci (1994) 14:3180-94.
55. Heckers S, Konradi C. GABAergic mechanisms of hippocampal hyperactivity in schizophrenia. Schizophr Res (2015) 167:4-11. doi:10.1016/j.schres.2014.09.041
56. Wang AY, Lohmann KM, Yang CK, Zimmerman EI, Pantazopoulos H, Herring N, et al. Bipolar disorder type 1 and schizophrenia are accompanied by decreased density of parvalbumin-and somatostatin-positive interneurons in the parahippocampal region. Acta Neuropathol (2011) 122:615-26. doi:10.1007/s00401-011-0881-4
57. Konradi C, Yang CK, Zimmerman EI, Lohmann KM, Gresch P, Pantazopoulos H, et al. Hippocampal interneurons are abnormal in schizophrenia. Schizophr Res (2011) 131:165-73. doi:10.1016/j.schres.2011.06.007
58. Suryavanshi PS, Ugale RR, Yilmazer-Hanke D, Stairs DJ, Dravid SM. GluN2C/GluN2D subunit-selective NMDA receptor potentiator CIQ reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice. Br J Pharmacol (2014) 171:799-809. doi:10.1111/bph.12518
59. Sapkota K, Mao Z, Synowicki P, Lieber D, Liu M, Ikezu T, et al. GluN2D N-methyl-d-aspartate receptor subunit contribution to the stimulation of brain activity and gamma oscillations by ketamine: implications for schizophrenia. J Pharmacol Exp Ther (2016) 356:702-11. doi:10.1124/jpet.115.230391
60. Yamamoto T, Nakayama T, Yamaguchi J, Matsuzawa M, Mishina M, Ikeda K, et al. Role of the NMDA receptor GluN2D subunit in the expression of ketamine-induced behavioral sensitization and region-specific activation of neuronal nitric oxide synthase. Neurosci Lett (2016) 610:48-53. doi:10.1016/j.neulet.2015.10.049
61. Yamamoto H, Kamegaya E, Sawada W, Hasegawa R, Yamamoto Y, Hagino Y, et al. Involvement of the N-methyl-d-aspartate receptor GluN2D subunit in phencyclidine-induced motor impairment, gene expression, and increased Fos immunoreactivity. Mol Brain (2013) 6:56. doi:10.1186/1756-6606-6-56
62. Hagino Y, Kasai S, Han W, Yamamoto H, Nabeshima T, Mishina M, et al. Essential role of NMDA receptor channel e4 subunit (GluN2D) in the effects of phencyclidine, but not methamphetamine. PLoS One (2010) 5:e13722. doi:10.1371/journal.pone.0013722
63. Jones RS, Buhl EH. Basket-like interneurones in layer II of the entorhinal cortex exhibit a powerful NMDA-mediated synaptic excitation. Neurosci Lett (1993) 149:35-9. doi:10.1016/0304-3940(93)90341-H
64. Cohen SM, Tsien RW, Goff DC, Halassa MH. The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia. Schizophr Res (2015) 167:8-107. doi:10.1016/j.schres.2014.12.026
65. Wang XJ. Neurophysiological and computational principles of cortical rhythms in cognition. Physiol Rev (2010) 90:1195-268. doi:10.1152/physrev.00035.2008
66. Buzsáki G, Wang XJ. Mechanisms of gamma oscillations. Annu Rev Neurosci (2012) 35:203-25. doi:10.1146/annurev-neuro-062111-150444
67. Jadi MP, Behrens MM, Sejnowski TJ. Abnormal gamma oscillations in N-methyl-d-aspartate receptor hypofunction models of schizophrenia. Biol Psychiatry (2016) 79:716-26. doi:10.1016/j.biopsych.2015.07.005
68. Gonzalez-Burgos G, Lewis DA. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophr Bull (2012) 38:950-7. doi:10.1093/schbul/sbs010
69. McNally JM, McCarley RW. Gamma band oscillations: a key to understanding schizophrenia symptoms and neural circuit abnormalities. Curr Opin Psychiatry (2016) 29:202-10. doi:10.1097/YCO.0000000000000244
70. Ford JM, Krystal JH, Mathalon DH. Neural synchrony in schizophrenia: from networks to new treatments. Schizophr Bull (2007) 33:848-52. doi:10.1093/schbul/sbm062
71. Ward LM. Synchronous neural oscillations and cognitive processes. Trends Cogn Sci (2003) 7:553-9. doi:10.1016/j.tics.2003.10.012
72. Fries P. Neuronal gamma-band synchronisation as a fundamental process in cortical computation. Annu Rev Neurosci (2009) 32:209-24. doi:10.1146/annurev.neuro.051508.135603
73. Pulvermüller F, Birbaumer N, Lutzenberger W, Mohr B. High-frequency brain activity: its possible role in attention, perception and language processing. Prog Neurobiol (1997) 52:427-45. doi:10.1016/S0301-0082(97)00023-3
74. Garagnani M, Lucchese G, Tomasello R, Wennekers T, Pulvermüller F. A spiking neurocomputational model of high-frequency oscillatory brain responses to words and pseudowords. Front Comput Neurosci (2017) 10:145. doi:10.3389/fncom.2016.00145
75. Gandal MJ, Edgar JC, Klook K, Siegel SJ. Gamma synchrony: towards a translational biomarker for the treatment resistant symptoms of schizophrenia. Neuropharmacology (2012) 62:1504-18. doi:10.1016/j.neuropharm.2011.02.007
76. Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci (2010) 11:100-13. doi:10.1038/nrn2774
77. Hirano Y, Oribe N, Kanba S, Onitsuka T, Nestor PG, Spencer KM. Spontaneous gamma activity in schizophrenia. JAMA Psychiatry (2015) 72(8):813-21. doi:10.1001/jamapsychiatry.2014.2642
78. Castelnovo A, Ferrarelli F, D'Agostino A. Schizophrenia: from neurophysiological abnormalities to clinical symptoms. Front Psychol (2015) 6:478. doi:10.3389/fpsyg.2015.00478
79. Lewis DA, Curley AA, Glausier JR, Volk DW. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci (2012) 35(1):57-67. doi:10.1016/j.tins.2011.10.004
80. Lucchese G. Confronting JC virus and Homo sapiens biological signatures. Front Biosci (2013) 18:716-24. doi:10.2741/4133
81. Lucchese G, Capone G, Kanduc D. Peptide sharing between influenza A H1N1 hemagglutinin and human axon guidance proteins. Schizophr Bull (2014) 40:362-75. doi:10.1093/schbul/sbs197
82. Lucchese G. Understanding neuropsychiatric diseases, analysing the peptide sharing between infectious agents and the language-associated NMDA 2A protein. Front Psychiatry (2016) 7:60. doi:10.3389/fpsyt.2016.00060